A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Mise à jour : Il y a 4 ans
Référence : NCT01529515

Femme et Homme

Extrait

The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.


Critère d'inclusion

  • Schizophrenia


Liens